Three-dimensional structure-activity relationship modeling of cocaine binding to two monoclonal antibodies by comparative molecular field analysis

Journal of Molecular Biology

Volumn 325, Issue 3, 2003, Pages 515-530

  Paula, Stefan ^a   Tabet, Michael R ^a   Keenan, Susan M ^b   Welsh, William J ^b   Ball Jr , William James ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

3D QSAR; Cocaine; Cocaine binding; CoMFA; Monoclonal antibodies

Indexed keywords

BIOPOLYMER; COCAINE; COCAINE DERIVATIVE; DOPAMINE TRANSPORTER; ESTER DERIVATIVE; MONOCLONAL ANTIBODY; PHENYL GROUP; RADIOLIGAND;

ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; ELECTRICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOTHERAPY; LIGAND BINDING; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

MURINAE;

EID: 0037230101     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2836(02)01235-4     Document Type: Article

References (38)

1. Butler, V. P. & Chen, J. P. (1967). Digoxin-specific antibodies. Proc. Natl. Acad. Sci. USA, 57, 71-78.
2. Schmidt, D. H. & Butler, V. P. (1971). Reversal of digoxin toxicity with specific antibodies. J. Clin. Invest. 50, 1738-1744.
3. Schmidt, D. H. & Butler, V. P. (1971). Immunological protection against digoxin toxicity. J. Clin. Invest. 50, 866-871.
4. Smith, T. W., Haber, E., Yeatman, L. & Butler, V. P. (1976). Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N. Engl. J. Med. 294, 797-800.
5. Bonese, K. F., Wainer, B. H., Fitch, F. W., Rothberg, R. M. & Schuster, C. R. (1974). Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature, 252, 708-710.
6. Carrera, M. R., Ashley, J. A., Parsons, L. H., Wirsching, P., Koob, G. F. & Janda, K. D. (1995). Suppression of psychoactive effects of cocaine by active immunization. Nature, 378, 727-730.
7. Carrera, M. R., Ashley, J. A., Wirsching, P., Koob, G. F. & Janda, K. D. (2001). A second-generation vaccine protects against the psychoactive effects of cocaine. Proc. Natl. Acad. Sci. USA, 98, 1988-1992.
8. Kantak, K. M., Collins, S. L., Lipman, E. G., Bond, J., Giovanoni, K. & Fox, B. S. (2000). Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology, 148, 251-262.
9. Ettinger, R. H., Ettinger, W. F. & Harless, W. E. (1997). Active immunization with cocaine-protein conjugate attenuates cocaine effects. Pharmacol. Biochem. Behav. 58, 215-220.
10. Harlow, E. & Lane, D. (1999). Using Antibodies. A Laboratory Manual, chapt. 2. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
11. Larsen, A. L., Zhou, B., Heine, A., Wirsching, P., Janda, K. D. & Wilson, I. A. (2001). Crystal structure of a cocaine-binding antibody. J. Mol. Biol. 311, 9-15.
12. Cramer, R. D., III, Patterson, D. E. & Bunce, J. D. (1988). Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110, 5959-5967.
13. Green, S. M. & Marshall, G. R. (1995). 3D-QSAR: A current perspective. Trends Pharmacol. Sci. 16, 285-291.
14. Tong, W., Perkins, R., Strelitz, R., Collantes, E. R., Keenan, S., Welsh, W. J. et al. (1997). Quantitative structure-activity relationships (QSARs) for estrogen binding to the estrogen receptor: Predictions across species. Environ. Health Perspect. 105, 1116-1124.
15. Farr, C. D., Burd, C., Tabet, M. R., Wang, X., Welsh, W. J. & Ball, W. J. (2002). Three-dimensional quantitative structure-activity relationship study of the inhibition of Na(+),K(+)-ATPase by cardiotonic steroids using comparative molecular field analysis. Biochemistry 41, 1137-1148.
16. Jayatilleke, P. R., Nair, A. C., Zauhar, R. & Welsh, W. J. (2000). Computational studies on HIV-1 protease inhibitors: Influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models. J. Med. Chem. 43, 4446-4451.
17. Chavatte, P., Yous, S., Marot, C., Baurin, N. & Lesieur, D. (2001). Three-dimensional quantitative structure-activity relationships of cyclooxygenase-2 (COX-2) inhibitors: A comparative molecular field analysis. J. Med. Chem. 27, 3223-3230.
18. Farr, C. D., Tabet, M. R., Ball, W. J., Fishwild, D. M., Wang, X., Nair, A. C. & Welsh, W. J. (2002). Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis. J. Med. Chem. 45, 3257-3270.
19. 3H]cocaine binding sites in caudate-putamen. J. Pharmacol. Expt. Ther. 251, 131-141.
20. Carroll, F. I., Leonard, L. H. & Kuhar, M. J. (1999). Pharmacotherapies for treatment of cocaine abuse: Preclinical aspects. J. Med. Chem. 42, 2721-2736.
21. Katzung, B. G. (ed.) (2001). Basic Clinical Pharmacology, McGraw-Hill Companies, Inc, New York.
22. Carroll, F. I., Mascarella, S. W., Kuzemko, M. A., Gao, Y., Abraham, P., Lewin, A. H. et al. (1994). Synthesis, ligand binding, and QSAR (CoMFA and classical) study of 3β-(3′-substituted phenyl)-, 3β-(4′-substituted phenyl)-, and 3β-(3′,4′-disubstituted phenyl)tropane-2β-carboxylic acid methyl esters. J. Med. Chem. 37, 2865-2873.
23. Carroll, F. I., Gao, Y. G., Rahman, M. A., Abraham, P., Parham, K., Lewin, A. H., Boja, J. W. & Kuhar, M. J. (1991). Synthesis, ligand binding, QSAR, and CoMFA study of 3β-(p-substituted phenyl)tropane-2β-carboxylic acid methyl esters. J. Med. Chem. 34, 2719-2725.
24. Newman, A. H., Izenwasser, S., Robarge, M. J. & Kline, R. H. (1999). CoMFA study of novel phenyl ring-substituted 3α-(diphenylmethoxy)tropane analogues at the dopamine transporter. J. Med. Chem. 42, 3502-3509.
25. Carroll, F. I., Kotian, P., Dehghani, A., Gray, J. L., Kuzemko, M. A., Parham, K. A., Abraham, P., Lewin, A. H., Boja, J. W. & Kuhar, M. J. (1995). Cocaine and 3β-(4′-substituted phenyl)tropane-2β-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter. J. Med. Chem. 38, 379-388.
26. Lieske, S. F., Yang, B., Eldefrawi, M. E., MacKerell, A. D. & Wright, J. (1998). (-)-3β-substituted ecgonine methyl esters as inhibitors for cocaine binding and dopamine uptake. J. Med. Chem. 41, 864-876.
27. Javaid, J. I., Fischman, M. W., Schuster, C. R., Dekirmenjian, H. & Davis, J. M. (1978). Cocaine plasma concentration: Relation to physiological and subjective effects in humans. Science, 202, 227-228.
28. Karch, S. B. (1996). The Pathology of Drug Abuse, chapt. 1, CRC Press, Inc, Boca Raton, FL.
29. Pimentel, G. C. & McClellan, A. L. (1960). The Hydrogen Bond, Freeman, San Francisco.
30. Jeffrey, P. D., Schildbach, J. F., Chang, C. Y., Kussie, P. H., Margolies, M. N. & Sheriff, S. (1995). Structure and specificity of the anti-digoxin antibody 40-50. J. Mol. Biol. 248, 344-360.
31. Lim, K., Owens, S. M., Arnold, L., Sacchettini, J. C. & Linthicum, D. S. (1998). Crystal structure of monoclonal 6B5 Fab complexed with phencyclidine. J. Biol. Chem. 273, 28576-28582.
32. Arevalo, J. H., Stura, E. A., Taussig, M. J. & Wilson, I. A. (1993). Three-dimensional structure of an anti-steroid Fab′ and progesterone-Fab′ complex. J. Mol. Biol. 231, 103-118.
33. Benowitz, N. L. (1993). Clinical pharmacology and toxicology of cocaine. Pharmacol. Toxicol. 72, 3-12.
34. Leshner, A. (1996). Molecular mechanisms of cocaine addiction. N. Engl. J. Med. 335, 128-129.
35. Johanson, C.-E. & Fischman, M. W. (1989). The pharmacology of cocaine related to its abuse. Pharmacol. Rev. 41, 3-52.
36. Chen, N. & Reith, M. E. A. (2000). Structure and function of the dopamine transporter. Eur. J. Pharmacol. 405, 329-339.
37. +-ATPase. Biochemistry, 37, 6658-6666.
38. 50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108.